198 related articles for article (PubMed ID: 18077611)
1. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax.
Gilderman LI; Lawless JF; Nolen TM; Sterling T; Rutledge RZ; Fernsler DA; Azrolan N; Sutradhar SC; Wang WW; Chan IS; Schlienger K; Schödel F; Silber JL;
Clin Vaccine Immunol; 2008 Feb; 15(2):314-9. PubMed ID: 18077611
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.
Kerzner B; Murray AV; Cheng E; Ifle R; Harvey PR; Tomlinson M; Barben JL; Rarrick K; Stek JE; Chung MO; Schödel FP; Wang WW; Xu J; Chan IS; Silber JL; Schlienger K
J Am Geriatr Soc; 2007 Oct; 55(10):1499-507. PubMed ID: 17908055
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of ZOSTAVAX(®) approaching expiry potency in individuals aged ≥50 years.
Arnou R; Fiquet A; Thomas S; Sadorge C
Hum Vaccin; 2011 Oct; 7(10):1060-5. PubMed ID: 21941091
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids.
Russell AF; Parrino J; Fisher CL; Spieler W; Stek JE; Coll KE; Su SC; Xu J; Li X; Schlienger K; Silber JL
Vaccine; 2015 Jun; 33(27):3129-34. PubMed ID: 25964168
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.
Levin MJ; Buchwald UK; Gardner J; Martin J; Stek JE; Brown E; Popmihajlov Z
Vaccine; 2018 Jan; 36(1):179-185. PubMed ID: 28830693
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.
Mills R; Tyring SK; Levin MJ; Parrino J; Li X; Coll KE; Stek JE; Schlienger K; Chan IS; Silber JL
Vaccine; 2010 Jun; 28(25):4204-9. PubMed ID: 20416263
[TBL] [Abstract][Full Text] [Related]
7. The immunogenicity and safety of zoster vaccine in Taiwanese adults.
Yao CA; Chen LK; Huang KC
Vaccine; 2015 Mar; 33(13):1515-7. PubMed ID: 25681662
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and Safety of a Live Attenuated Zoster Vaccine (ZOSTAVAX™) in Korean Adults.
Choi WS; Choi JH; Choi JY; Eom JS; Kim SI; Pai H; Peck KR; Sohn JW; Cheong HJ
J Korean Med Sci; 2016 Jan; 31(1):13-7. PubMed ID: 26770032
[TBL] [Abstract][Full Text] [Related]
9. Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Eberhardson M; Hall S; Papp KA; Sterling TM; Stek JE; Pang L; Zhao Y; Parrino J; Popmihajlov Z
Clin Infect Dis; 2017 Oct; 65(7):1174-1182. PubMed ID: 29126292
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults.
Macaladad N; Marcano T; Guzman M; Moya J; Jurado F; Thompson M; Meechan C; Li D; Schlienger K; Chan I; Sadoff J; Schödel F; Silber JL
Vaccine; 2007 Mar; 25(11):2139-44. PubMed ID: 17250932
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age.
Vermeulen JN; Lange JM; Tyring SK; Peters PH; Nunez M; Poland G; Levin MJ; Freeman C; Chalikonda I; Li J; Smith JG; Caulfield MJ; Stek JE; Chan IS; Vessey R; Schödel FP; Annunziato PW; Schlienger K; Silber JL
Vaccine; 2012 Jan; 30(5):904-10. PubMed ID: 22154769
[TBL] [Abstract][Full Text] [Related]
12. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inferiority clinical trial.
Diez-Domingo J; Weinke T; Garcia de Lomas J; Meyer CU; Bertrand I; Eymin C; Thomas S; Sadorge C
Vaccine; 2015 Feb; 33(6):789-95. PubMed ID: 25555381
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.
Godeaux O; Kovac M; Shu D; Grupping K; Campora L; Douha M; Heineman TC; Lal H
Hum Vaccin Immunother; 2017 May; 13(5):1051-1058. PubMed ID: 28068212
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity, Safety, and Tolerability of Live Attenuated VaricellaZoster Virus Vaccine (ZOSTAVAX™) in Healthy Adults in India.
Sreenivasamurthy L; Pandey S; Chandra BS; Sharma M; Ranganathaiah SR; Vaidya P; Naik R
J Assoc Physicians India; 2018 Jul; 66(7):50-54. PubMed ID: 31325263
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax® in healthy adults aged 50 years and older.
Choi WS; Choi JH; Jung DS; Choi HJ; Kim YS; Lee J; Jang HC; Shin EC; Park JS; Kim H; Cheong HJ
Vaccine; 2019 Jun; 37(27):3605-3610. PubMed ID: 31122860
[TBL] [Abstract][Full Text] [Related]
16. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old.
MacIntyre CR; Egerton T; McCaughey M; Parrino J; Campbell BV; Su SC; Pagnoni MF; Stek JE; Xu J; Annunziato PW; Chan IS; Silber JL
Hum Vaccin; 2010 Nov; 6(11):894-902. PubMed ID: 20980796
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules.
Vesikari T; Hardt R; Rümke HC; Icardi G; Montero J; Thomas S; Sadorge C; Fiquet A
Hum Vaccin Immunother; 2013 Apr; 9(4):858-64. PubMed ID: 23319176
[TBL] [Abstract][Full Text] [Related]
18. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su.
Strezova A; Godeaux O; Aggarwal N; Leroux-Roels G; Lopez-Fauqued M; Van Damme P; Vanden Abeele C; Vastiau I; Heineman TC; Lal H
Vaccine; 2017 Dec; 35(48 Pt B):6700-6706. PubMed ID: 29079101
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older.
Sutradhar SC; Wang WW; Schlienger K; Stek JE; Xu J; Chan IS; Silber JL
Clin Vaccine Immunol; 2009 May; 16(5):646-52. PubMed ID: 19261769
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of a high-potency zoster vaccine in adults >/= 50 or years of age.
Tyring SK; Diaz-Mitoma F; Padget LG; Nunez M; Poland G; Cassidy WM; Bundick ND; Li J; Chan IS; Stek JE; Annunziato PW;
Vaccine; 2007 Feb; 25(10):1877-83. PubMed ID: 17227688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
